Literature DB >> 12676814

The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure.

Tong Zhang1, Lars S Maier, Nancy D Dalton, Shigeki Miyamoto, John Ross, Donald M Bers, Joan Heller Brown.   

Abstract

Recent studies have demonstrated that transgenic (TG) expression of either Ca2+/calmodulin-dependent protein kinase IV (CaMKIV) or CaMKIIdeltaB, both of which localize to the nucleus, induces cardiac hypertrophy. However, CaMKIV is not present in heart, and cardiomyocytes express not only the nuclear CaMKIIdeltaB but also a cytoplasmic isoform, CaMKIIdeltaC. In the present study, we demonstrate that expression of the deltaC isoform of CaMKII is selectively increased and its phosphorylation elevated as early as 2 days and continuously for up to 7 days after pressure overload. To determine whether enhanced activity of this cytoplasmic deltaC isoform of CaMKII can lead to phosphorylation of Ca2+ regulatory proteins and induce hypertrophy, we generated TG mice that expressed the deltaC isoform of CaMKII. Immunocytochemical staining demonstrated that the expressed transgene is confined to the cytoplasm of cardiomyocytes isolated from these mice. These mice develop a dilated cardiomyopathy with up to a 65% decrease in fractional shortening and die prematurely. Isolated myocytes are enlarged and exhibit reduced contractility and altered Ca2+ handling. Phosphorylation of the ryanodine receptor (RyR) at a CaMKII site is increased even before development of heart failure, and CaMKII is found associated with the RyR in immunoprecipitates from the CaMKII TG mice. Phosphorylation of phospholamban is also increased specifically at the CaMKII but not at the PKA phosphorylation site. These findings are the first to demonstrate that CaMKIIdeltaC can mediate phosphorylation of Ca2+ regulatory proteins in vivo and provide evidence for the involvement of CaMKIIdeltaC activation in the pathogenesis of dilated cardiomyopathy and heart failure.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  2003        PMID: 12676814     DOI: 10.1161/01.RES.0000069686.31472.C5

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  238 in total

Review 1.  Cardiac hypertrophy and heart failure development through Gq and CaM kinase II signaling.

Authors:  Shikha Mishra; Haiyun Ling; Michael Grimm; Tong Zhang; Don M Bers; Joan Heller Brown
Journal:  J Cardiovasc Pharmacol       Date:  2010-12       Impact factor: 3.105

Review 2.  CaMKII in myocardial hypertrophy and heart failure.

Authors:  Mark E Anderson; Joan Heller Brown; Donald M Bers
Journal:  J Mol Cell Cardiol       Date:  2011-01-27       Impact factor: 5.000

3.  Calcium/calmodulin-dependent protein kinase IIdelta associates with the ryanodine receptor complex and regulates channel function in rabbit heart.

Authors:  Susan Currie; Christopher M Loughrey; Margaret-Anne Craig; Godfrey L Smith
Journal:  Biochem J       Date:  2004-01-15       Impact factor: 3.857

4.  Fluorescence resonance energy transfer-based sensor Camui provides new insight into mechanisms of calcium/calmodulin-dependent protein kinase II activation in intact cardiomyocytes.

Authors:  Jeffrey R Erickson; Ruchi Patel; Amanda Ferguson; Julie Bossuyt; Donald M Bers
Journal:  Circ Res       Date:  2011-08-11       Impact factor: 17.367

5.  Differential effects of hypoxic and hyperoxic stress-induced hypertrophy in cultured chick fetal cardiac myocytes.

Authors:  Allison A Greco; George Gomez
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-08-29       Impact factor: 2.416

6.  CaMKII inhibition in heart failure, beneficial, harmful, or both.

Authors:  Jun Cheng; Lin Xu; Dongwu Lai; Arnaud Guilbert; Hyun Joung Lim; Thitima Keskanokwong; Yanggan Wang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-01-27       Impact factor: 4.733

7.  Network-based predictions of in vivo cardiac hypertrophy.

Authors:  Deborah U Frank; Matthew D Sutcliffe; Jeffrey J Saucerman
Journal:  J Mol Cell Cardiol       Date:  2018-07-17       Impact factor: 5.000

8.  The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload.

Authors:  Johannes Backs; Thea Backs; Stefan Neef; Michael M Kreusser; Lorenz H Lehmann; David M Patrick; Chad E Grueter; Xiaoxia Qi; James A Richardson; Joseph A Hill; Hugo A Katus; Rhonda Bassel-Duby; Lars S Maier; Eric N Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-28       Impact factor: 11.205

9.  Posttranslational modifications of calcium/calmodulin-dependent protein kinase IIδ and its downstream signaling in human failing hearts.

Authors:  Tomas Rajtik; Eva Goncalvesova; Zoltan V Varga; Przemyslaw Leszek; Mariusz Kusmierczyk; Michal Hulman; Jan Kyselovic; Peter Ferdinandy; Adriana Adameova
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

Review 10.  New therapeutic targets in cardiology: arrhythmias and Ca2+/calmodulin-dependent kinase II (CaMKII).

Authors:  Adam G Rokita; Mark E Anderson
Journal:  Circulation       Date:  2012-10-23       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.